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Abstract
Aims: The aim of this study was to evaluate the sensitivity of the long exercise test
(LET) in the diagnosis of periodic paralysis (PP) and assess correlations with clinical
phenotypes and genotypes.
Methods: From an unselected cohort of 335 patients who had an LET we analyzed
67 patients with genetic confirmation of PP and/or a positive LET.
Results: 32/45 patients with genetically confirmed PP had a significant decrement
after exercise (sensitivity of 71%). Performing the short exercise test before the LET
in the same hand confounded results in four patients. Sensitivity was highest in
patients with frequent (daily or weekly) attacks (8/8, 100%), intermediate with up to
monthly attacks (15/21, 71%) and lowest in those with rare attacks (9/16, 56%)
(p = .035, Mann–Whitney U-test). Patients with a positive LET without confirmed PP
mutation comprised those with typical PP phenotype and a group with atypical
features.
Discussion: In our cohort, the LET is strongly correlated with the frequency of para-
lytic attacks suggesting a role as a functional marker. A negative test in the context
of frequent attacks makes a diagnosis of PP unlikely but it does not rule out the con-
dition in less severely affected patients.
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1 | INTRODUCTION
The primary periodic paralyses (PP) are characterized by episodic mus-
cle weakness and include hypokalemic PP (hypoPP), hyperkalemic PP
(hyperPP) and Andersen-Tawil syndrome (ATS) due to mutations in
voltage gated ion channels.1,2 The diagnosis is based on clinical
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presentation supported by genetic and electrophysiological findings
but can be challenging when clinical and laboratory information do
not agree.3 Genetic testing has been the gold standard for diagnosis,
but a pathogenic mutation is found in only 60% to 70% of patients
meeting clinical criteria for PP.1 The literature suggests that the long
exercise test (LET) is highly sensitive and specific.4-10 The aim of this
study was to assess sensitivity in our cohort and correlate electro-
physiology with phenotype and genotype.
2 | METHODS
A retrospective analysis of patients attending the National Muscle
Channelopathy Service from 2009 to 2017 was performed to identify
all patients who had undergone an LET. The study was registered and
approved as part of a clinical audit with the National Hospital for Neu-
rology and Neurosurgery Audit Committee. Because the data was
obtained during routine clinical care and collected from hospital elec-
tronic records as part of a clinical audit, such evaluations do not require
patient consent. Patients were selected if they fulfilled at least one
criteria: a positive LET or a pathological variant in a PP associated gene.
Some patients in this study were included in a previous publication that
also contained data of normal controls for the LET.7 Patients were sub-
divided into three main groups: (a) genetics and LET positive, (b) genet-
ics positive and LET negative, and (c) genetics negative and LET
positive. Frequency of attacks was categorized as (1) none or rare (0-1/
year, this included patients with progressive weakness and no attacks),
(2) moderate (>1/year to monthly), and (3) frequent (weekly to daily).
2.1 | Genetics
Patients were considered to have genetically confirmed PP if patho-
genic PP mutations were found in relevant genes (CACNA1S, KCNJ2,
SCN4A, RYR1). Testing was done by direct Sanger sequencing (hotspot
testing in earlier cohorts or family mutations) or next generation
sequencing using a “muscle channel panel.”
2.2 | Neurophysiology
The LET was performed as described by McManis et al.4 Compound
muscle action potentials (CMAP) from abductor digiti minimi were
monitored at baseline, during 5 min of exercise and for 50 min post-
exercise. The same electrodes were used during short exercise test
(SET), which preceded the LET, when applicable with a maximum
interval between SET and LET of 30 min. A post-exercise decrement
of more than 40% from peak CMAP amplitude indicated a positive
test. As we previously observed a significant decrement occurring
after SET (3  10 s bouts of exercise separated by 1 min), we consid-
ered the LET positive if there was >40% decrement between peak
SET amplitude and the post-LET exercise CMAP. We used the largest
SET CMAP amplitude to calculate the overall decrement.
2.3 | Analysis
Sensitivity was calculated using genetic testing as the gold standard.
Statistical analysis was conducted using SPSS Statistics for Macintosh,
Version 25.0. (IBM, Armonk, NY). For individual tests see Table 1 and
Appendix S1, which is available online. The level of statistical signifi-
cance was set at p < .05.
3 | RESULTS
3.1 | Patient characteristics
We identified 335 patients who had undergone the LET, of which 248
had neither positive LET nor PP genetics. The presenting symptom
was intermittent paralysis and/or progressive muscle weakness. Anal-
ysis focused on 67 patients who had a positive LET and/or genetically
confirmed PP (Figure 1, Table 1). A total of 35 patients had an SET
prior to the LET. In six of these patients the calculated overall decre-
ment was >5%–10% larger and in nine patients >10% larger than the
decrement based on LET data alone, leading to re-classification of
four individuals from LET negative to LET positive. LET sensitivity was
71% and did not significantly differ between genotypes, although sub-
groups were small. Estimated LET specificity for genetically confirmed
PP was 92.4% (268/290) in the entire cohort undergoing an LET.
3.2 | Attack frequency and LET result
LET results correlated with frequency of attacks (p = .035, Mann–
Whitney U-test, Figure 2). More genetically confirmed PP patients
with a positive LET result were on PP treatment (20/32, 62.5%) com-
pared to those with a negative LET (3/13, 23.1%), p = .016.
3.3 | Positive LET but negative PP genetics
Typical PP features were seen in 10/22 patients with a positive LET
but negative PP genetics. 9/10 patients with typical PP phenotype
had negative genetic results after next generation sequencing of
CACNA1S, KCNJ2, and SCN4A genes. The nine patients with a mixed
or atypical phenotype presented with exercise-induced fatigue with
stiffness and cramps or exercise intolerance and fatigue.
3.4 | LET parameters and variability
A total of 16/67 patients had a repeat LET with a mean test-to-test
intra-individual CMAP amplitude decrement variability of 12% (range
2%–27%). There was no clear relationship between medication
changes and result of the repeat LET. Attack frequency data at the
time of repeat testing was not available in sufficient numbers for
analysis.
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LET positive p-Value Statistical test
Patients n = 32 n = 13 n = 22 N/A N/A
Age (y) 36.6 ± 14.2 (15–64) 44.4 ± 15.4 (18–77) 36.4 ± 12.8 (17–63) .197 ANOVA
Gender M/F (M:F ratio) 26/6 (4.3: 1) 8/5 (1.6: 1) 21/1 (21: 1) .040 Fisher
No. of patients on PP medication (%) 20 (62.5%) 3 (23.1%) 2 (9.1%)
Largest CMAP in mV 8.1 ± 1.8a (4.2–11.6) 9.1 ± 1.8 (4.4–12.8) 10.5 ± 2.1a (6.0–15.2) <.001 ANOVA
Increment in % 28.4 ± 26.4 (11–119) 11.8 ± 15.1 (13–48) 28.1 ± 14.9 (4–58) .017 Kruskal-Wallis
Decrement from peak in % 55.0 ± 11.6 (33–80) 28.7 ± 6.4 (15–39) 51.3 ± 8.4 (42–68) N/Ab N/A
Decrement from baseline in % 41.8 ± 19.1 (12–81) 20.1 ± 11.2 (0–38) 37.9 ± 12.2 (12–57) N/Ab N/A
Time to 40% decrement in minutes 21.4 ± 13.0c (4–54) N/A 28.7 ± 12.6 (3–46) .051 t
Note: Continuous quantitative data were plotted as mean ± SD (range).
Abbreviations: F, female; M, male; N/A, not applicable.
aGroups with statistically significant differences.
bStatistical analysis was not performed as group allocation was according to peak decrement.
cA total of 4/32 patients incorporated after SET calculations could not be included as a 40% decrement was not achieved during LET.
F IGURE 1 Study sample.
There was no statistically
significant correlation between
the LET results and genotype (X2
p = .625). Patients with
paramyotonia congenita (PMC)
were not included in the main
sample as the LET pattern is
often different from periodic
paralysis and a positive LET is not
a diagnostic criterium for this
condition, which has a typical
response pattern on SET
particularly after cooling
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4 | DISCUSSION
Our study demonstrates that the sensitivity of the LET is strongly cor-
related with disease activity. All patients with frequent attacks had a
positive LET compared to just over half of those with rare attacks or
progressive weakness. This confirms that patients who have more fre-
quent spontaneous attacks of weakness are more likely to have an
attack following a standardized provocation maneuver. It is also useful
in clinical practice as it indicates patients with frequent attacks but
negative LET are unlikely to have PP, whereas those with rare attacks
and negative LET should be considered for genetic testing if clinical
suspicion is strong. Our findings correlate with the observation by
Tengan et al11 who investigated 14 individuals from two families with
hypoPP and four individuals with thyrotoxic periodic paralysis and
found a positive LET only in patients with recent PP attacks while
individuals with no recent attacks had a negative LET. We show that
this can be applied to an unselected PP cohort of hypoPP, hyperPP
and ATS. It is known that women with PP are often less severely
affected and more likely to present with progressive weakness,8-11
which correlates with the larger number of women in the negative
LET group in our study.
Even patients with rare discrete attacks of paralysis may report
frequent fluctuations of strength and this could explain why a number
of patients in this group still have a positive LET. Indeed a positive
LET may indicate a treatable element of their condition, which can be
difficult to distinguish clinically from the progressive myopathy that
develops later in the disease. This hypothesis could be investigated by
correlating LET with muscle MRI as a means of differentiating
between reversible oedema versus irreversible fatty infiltration.
In several patients the SET confounded LET results by inducing a
significant decrement on its own. Our practice is to perform the SET
at room temperature and after cooling in one hand and the LET in the
other hand if both are required.
The sensitivity of 71% seen in this study is within the lower range
of published data (71% to 95%5-7). This may reflect identification of
patients with milder disease in more recent years due to better recog-
nition of the clinical phenotype and wider availability of comprehen-
sive genetic testing.
Previous studies have focused on improving the sensitivity of the
LET including lowering the upper limits of normal.9 Simmons et al12
applied Bayesian principles and elegantly showed that a higher sensi-
tivity/specificity may be achieved using different cutoff values by
incorporating pre-test probabilities. In practice this approach may be
difficult if patients are seen by clinicians unfamiliar with these rare
disorders.
In patients with typical PP phenotype but negative genetics sec-
ondary causes of PP should be considered but none were identified in
our cohort. Patients with a positive LET, negative PP genetics, and
atypical phenotype are an interesting group with likely heterogeneous
underlying pathology. Two of the patients had mutations in the
CACNA1A gene, encoding a calcium channel expressed in the central
and peripheral nervous system and linked to episodic ataxia.13 A
patient presenting with paralytic attacks and a novel CACNA1A muta-
tion but with a negative long exercise test has been reported
recently.14 We now routinely screen patients with strong clinical evi-
dence of periodic paralysis and negative PP genetics for CACNA1A
mutations.
Limitations of this study included incomplete clinical data due to
the retrospective nature, small subgroups, different operators and
equipment over time potentially introducing variability.
We propose a re-appraisal of the role of the LET in the diagnosis
of primary PP in the context of improved access to genetic evaluation.
F IGURE 2 Frequency of
attacks in patients with
genetically confirmed PP and
correlation with long exercise test
(LET) results, p = .035 (Mann–
Whitney U-test)
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In the past, it was used as a standard diagnostic test to rule-in or rule-
out the diagnosis. In patients with frequent attacks this remains a use-
ful strategy but in those with less severe or less frequent episodes of
weakness and/or atypical clinical features caution is needed in inter-
preting a negative LET. Our data suggest that the LET can be regarded
as a functional marker of PP, and, in patients who describe fixed but
fluctuating weakness; it may indicate benefit can still be derived from
pharmacological therapy.
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